Glycylvaline

Glycylvaline is a dipeptide, a molecule composed of two amino acids, glycine and valine, joined together by a peptide bond. Dipeptides are fundamental units in the synthesis of larger proteins and can also act independently, participating in various metabolic processes and cellular signaling pathways throughout the body.

Biological Basis

As a component of proteins, the amino acid valine, which forms part of glycylvaline, plays a significant role in certain post-translational modifications. Notably, glycated proteins are formed through a slow, non-enzymatic reaction where glucose molecules attach to amino groups, including the N-terminal valine residues of proteins.^[1]This process, known as glycation, can alter protein structure and function. A key example is glycated hemoglobin (HbA1c), where glucose attaches to the N-terminal valine of the hemoglobin beta chain.^[1]

Clinical Relevance

The concentration of glycated hemoglobin is a critical biomarker in clinical medicine, providing an integrated measure of average blood glucose levels over the preceding 8–12 weeks.^[1]This assay offers a more reliable estimate of long-term glycemia compared to single blood glucose measurements and is widely utilized for diagnosing type 2 diabetes, monitoring glucose control in individuals with the condition, and assessing diabetes risk.^[1]Studies have shown that genetic variations can influence glycated hemoglobin levels, even in individuals without diabetes.^[1] For instance, genes such as HK1, GCK, and SLC30A8have been associated with variations in glycated hemoglobin concentrations, highlighting the genetic factors involved in glucose regulation and susceptibility to type 2 diabetes.^[1]

Social Importance

Understanding glycylvaline and the broader process of glycation, particularly involving amino acids like valine, is crucial for public health initiatives. Glycated hemoglobin serves as an indispensable tool in the prevention, diagnosis, and management of type 2 diabetes, a major global health concern.^[1]Continued research into the genetic determinants influencing glycation pathways contributes to a deeper understanding of the complex interactions between genetics, metabolism, and disease risk, potentially paving the way for improved diagnostic methods and more personalized treatment strategies for metabolic disorders.

Limitations

Methodological and Statistical Constraints

Genome-wide association studies (GWAS) frequently encounter methodological and statistical challenges that can influence the interpretation of findings for traits like glycylvaline. Many studies rely on fixed-effects meta-analysis, which, while useful, may not fully capture the true heterogeneity between different cohorts, potentially leading to an overestimation of significance or an inaccurate assessment of effect sizes.^[2]A further limitation arises from the incomplete coverage of genetic variation by the genotyping arrays used; if the causal variants for glycylvaline are not directly genotyped or in strong linkage disequilibrium with the assayed single nucleotide polymorphisms (SNPs), they may be missed, thereby limiting the comprehensiveness of genetic discovery.^[3] The immense number of statistical tests performed in GWAS necessitates stringent significance thresholds, such as Bonferroni correction, which can increase the risk of false negatives by reducing the power to detect true associations with modest effect sizes, especially when reporting less stringently significant variants. ^[4]

These statistical hurdles are compounded by challenges in replication, which is considered the gold standard for validating GWAS findings. ^[4]Differences in study design, statistical power, and the specific SNPs covered by genotyping platforms across various cohorts can lead to non-replication at the individual SNP level, even if different variants within the same gene are associated with glycylvaline levels.^[5]Moreover, the decision to perform only sex-pooled analyses, often driven by concerns about increasing the multiple testing burden, means that sex-specific genetic effects on glycylvaline, which could offer crucial biological insights, might remain undetected.^[3]Addressing these constraints often requires larger sample sizes and improved statistical power to identify additional variants influencing glycylvaline and to ensure robust replication.

Limited Generalizability Across Ancestries

A substantial limitation observed in many GWAS, including those that might investigate glycylvaline, is the predominant focus on populations of European ancestry.^[1] While careful measures are often taken to account for population stratification within these cohorts, such as genomic control or principal component analysis, the findings may not be directly transferable or generalizable to individuals from other ethnic backgrounds. ^[6]This demographic imbalance in study populations restricts the broad applicability of any identified genetic associations for glycylvaline, as allele frequencies, patterns of linkage disequilibrium, and environmental exposures can vary significantly across diverse ancestral groups.

The lack of comprehensive multi-ethnic representation in discovery and replication cohorts implies that important genetic variants influencing glycylvaline levels in non-European populations may remain undiscovered.^[7]Although some studies have initiated efforts to validate findings in multi-ethnic samples, the primary research often originates from European-descent populations, highlighting a critical gap in fully understanding the genetic architecture of glycylvaline across the spectrum of human diversity.^[7] This limitation underscores the need for more inclusive study designs to ensure that genetic insights are equitable and broadly applicable.

Phenotypic Complexity and Environmental Influences

The accurate measurement and definition of complex phenotypes, such as glycylvaline levels, present inherent challenges in genetic research. While studies may employ sophisticated methods, including statistical transformations to achieve normality or the use of metabolite ratios to reduce variance and enhance statistical power, the intricate biological nature of the trait can still introduce variability and complexity.^[4]Standard practice involves adjusting for known clinical covariates like age, sex, and body mass index to minimize their confounding effects on association analyses; however, the potential influence of unmeasured or unknown confounders on glycylvaline levels cannot be entirely ruled out.^[1]

Critically, genetic associations are frequently influenced by environmental factors, leading to context-specific effects. ^[8]The current absence of extensive investigations into gene-environment interactions means that the complete etiological picture of how genetic variants interact with various lifestyle factors, dietary components, or other environmental exposures to modulate glycylvaline levels remains largely unexplored.^[8] This limits the depth of mechanistic understanding for identified genetic loci and their potential for clinical translation, necessitating further functional validation and dedicated studies designed to unravel complex gene-environment interplay. ^[9]

Variants

Genetic variations, including single nucleotide polymorphisms (SNPs) and alterations within pseudogenes or non-coding regions, can significantly influence an individual’s metabolic profile and susceptibility to various traits. These variants often impact gene expression, protein function, or cellular pathways, leading to subtle yet widespread effects on the body’s biochemistry. The dipeptide glycylvaline, like other small metabolites, is subject to these genetic influences, as its levels can be modulated by alterations in amino acid metabolism, protein turnover, or transport mechanisms.

The uncharacterized genetic variant rs2065946 , along with variations in the pseudogenes RPL21P24 and ATP6V0E1P4, represent diverse types of genetic influences. RPL21P24 and ATP6V0E1P4 are processed pseudogenes, which are non-functional copies of active genes, typically lacking introns and often not translated into proteins. While traditionally considered “junk DNA,” pseudogenes can exert regulatory control by influencing the expression of their functional parent genes or acting as competing endogenous RNAs. ^[10]Therefore, variants within or near these pseudogenes, even without directly altering protein-coding sequences, could subtly affect gene regulation or RNA stability. Such changes in gene expression or regulatory networks have broad impacts on cellular function and metabolism, potentially influencing levels of various biomolecules, including dipeptides like glycylvaline.^[4] Similarly, an uncharacterized SNP like rs2065946 could reside in a non-coding region, an intron, or intergenic space, where it might affect gene splicing, transcription factor binding, or chromatin structure, collectively contributing to individual differences in metabolic profiles.

Variations in genes encoding essential cellular machinery, such as DNAH11 and PRKCQ, can also have profound metabolic implications. The DNAH11 gene encodes a heavy chain protein crucial for dynein motor proteins, which are responsible for the movement of cilia and flagella and for intracellular transport. A variant like rs12533084 in DNAH11 could alter the structure or function of these motor proteins, potentially leading to impaired ciliary activity or defects in cellular cargo transport. ^[5]These cellular dysfunctions can have wide-ranging effects on organ systems and metabolic processes; for example, compromised cellular transport could indirectly impact nutrient processing or waste removal, which might affect the concentrations of various metabolites, including glycylvaline. In parallel,PRKCQencodes Protein Kinase C theta, an enzyme predominantly expressed in T lymphocytes and skeletal muscle, playing a vital role in immune cell activation and insulin signaling. A variant such asrs521153 in PRKCQcould modify the kinase’s activity or its interactions with other proteins, thereby influencing immune responses or metabolic pathways related to glucose uptake and energy regulation.^[11]Such alterations could lead to systemic metabolic changes that impact the availability or utilization of amino acids and dipeptides like glycylvaline.

Other variants affect genes involved in protein degradation, RNA regulation, and cell signaling, each with potential downstream effects on metabolism. NDFIP1 (Nedd4 family-interacting protein 1) is an adaptor protein that interacts with Nedd4 family E3 ubiquitin ligases, playing a critical role in protein ubiquitination and degradation pathways essential for maintaining cellular protein homeostasis. A variant like rs13185299 in NDFIP1 might alter its ability to recruit ubiquitin ligases, thereby affecting the stability or turnover of key cellular proteins, which could lead to a cascade of effects on cell signaling, growth, and metabolism ^[10]potentially influencing the balance of amino acids and small peptides like glycylvaline within the cell.LINC02573 is a long intergenic non-coding RNA (lincRNA), a class of RNA molecules increasingly recognized for their diverse regulatory roles in gene expression, chromatin remodeling, and various cellular processes. While the precise function of LINC02573 is still being elucidated, a variant such as rs2826076 could impact its expression, stability, or interaction with other molecules, thereby modulating the expression of nearby or distant genes. ^[4] Such regulatory shifts can have significant, albeit indirect, effects on metabolic pathways. Lastly, GIPC2 (GIPC PDZ domain containing family, member 2) encodes a protein with a PDZ domain, typically involved in scaffolding membrane proteins and receptors, facilitating their trafficking and signaling. A variant like rs12758374 in GIPC2could disrupt these protein-protein interactions, altering the localization or activity of crucial transporters or signaling molecules, thereby affecting cellular nutrient uptake, waste excretion, or signal transduction—all fundamental to maintaining metabolic balance and potentially influencing the concentrations of various metabolites, including glycylvaline.

Key Variants

RS ID	Gene	Related Traits
rs2065946	RPL21P24 - ATP6V0E1P4	glycylvaline measurement
rs12533084	DNAH11	glycylvaline measurement
rs521153	PRKCQ	glycylvaline measurement
rs13185299	NDFIP1	glycylvaline measurement lipid measurement
rs2826076	LINC02573	glycylvaline measurement
rs12758374	GIPC2	glycylvaline measurement lipid measurement

Biological Background

Molecular Foundations of Protein Glycation and Valine’s Significance

Glycated proteins are formed post-translationally through the slow, non-enzymatic attachment of glucose to specific amino acid residues, notably N-terminal valine and internal lysine amino groups. This chemical modification, known as glycation, is a direct consequence of glucose exposure in the body and is critical for understanding long-term glycemic status. The most clinically relevant example is glycated hemoglobin, often referred to as HbA1c, which forms when glucose binds to the N-terminal valine of hemoglobin within red blood cells.^[1]

The concentration of glycated hemoglobin is directly proportional to the average blood glucose levels to which erythrocytes have been exposed over their lifespan, typically around 120 days. Consequently, the glycated hemoglobin assay provides an integrated estimate of mean glycemia over the preceding 8–12 weeks. This makes it an indispensable biomarker for both diagnosing and monitoring glycemic control in individuals, particularly those with or at risk of type 2 diabetes.^[1]

Interconnected Metabolic Pathways and Key Biomolecules

Beyond its role in glycation, valine is a hydrophobic amino acid whose structural characteristics are important for protein function, where even seemingly conservative substitutions, such as Val253Ile in theGLUT9 protein, can lead to altered protein structure and function. ^[12]Glucose metabolism is a tightly regulated network involving key enzymes like hexokinase 1 (HK1), glucokinase (GCK), and glucose-6-phosphatase catalytic subunit 2 (G6PC2), with genetic variants in these genes influencing fasting blood glucose levels and glycated hemoglobin concentrations.^[1]

Furthermore, the glucose transporterGLUT9 (SLC2A9) plays a significant role in uric acid homeostasis, being primarily expressed in kidney proximal tubules where it is crucial for renal uric acid regulation and clearance.^[12]Disruptions in these metabolic pathways, such as the aldolase deficiency observed in hereditary fructosemia, can lead to a cascade of metabolic imbalances including hypoglycemia and hyperuricemia, underscoring the intricate and interdependent nature of metabolic health.^[12] The upregulation of GLUT9in diabetic rats suggests a potential link between the metabolic syndrome and hyperuricemia, indicating a complex interplay between glucose and uric acid regulation.^[12]

Genetic Regulation of Metabolic Traits and Protein Function

Genetic variations significantly influence an individual’s susceptibility to metabolic disorders and play a role in regulating glucose concentration even in healthy individuals.^[1]For instance, specific single nucleotide polymorphisms (SNPs) in genes likeHK1have been associated with variations in glycated hemoglobin levels, while variants inGCK and G6PC2are linked to fasting blood glucose concentrations.^[1] Beyond direct coding changes, regulatory elements affecting gene expression are crucial; an intronic variant (rs3846662 ) in HMGCR, for example, alters the efficiency of exon13 alternative splicing, thereby influencing the levels of alternatively spliced HMGCR mRNA. ^[13]

Such genetic influences extend to the composition of key biomolecules, where polymorphisms in the FADS1 gene cluster are associated with the fatty acid composition in phospholipids, demonstrating a genetically determined “metabotype”. ^[4] These genetic mechanisms also involve intricate regulatory networks where transcription factors, such as HNF-1, can synergistically trans-activate gene promoters, as observed for the human C-reactive protein promoter, thereby controlling the expression of proteins involved in inflammatory and metabolic responses. ^[14]

Pathophysiological Consequences and Systemic Interactions

Dysregulation of metabolic processes, including those involving valine and glucose, has profound pathophysiological consequences, most notably contributing to type 2 diabetes, a leading cause of morbidity and mortality worldwide.^[1]The measurement of glycated hemoglobin serves as a crucial diagnostic and monitoring tool for this condition, providing insights into long-term glycemic control and treatment efficacy.^[1]Beyond glucose, disruptions in uric acid homeostasis, often linked to the function ofGLUT9, can lead to hyperuricemia, which is a significant risk factor for conditions such as gout, kidney stones, and various components of the metabolic syndrome.^[12]

These metabolic imbalances often manifest with organ-specific effects, such as the critical role of GLUT9in renal uric acid clearance by kidney proximal tubules and the systemic exposure of erythrocytes to glucose that drives hemoglobin glycation.^[12] Moreover, severe systemic disorders, including hypoketotic hypoglycemia, lethargy, encephalopathy, and seizures, can arise from deficiencies in enzymes like those encoded by the FADS1 gene, further emphasizing the widespread and interconnected impact of metabolic health on overall physiological function. ^[4]

Pathways and Mechanisms

Metabolic Homeostasis and Regulation

The regulation of metabolic processes, including energy metabolism, biosynthesis, and catabolism, is central to maintaining cellular and organismal function. Key pathways involve the balanced processing of glucose and lipids, influenced by specific transporters and enzymes. For instance, the solute carrier family 2 member 9 (SLC2A9) plays a crucial role as a urate transporter, significantly influencing serum uric acid concentrations and excretion, and is also implicated in fructose metabolism.^[15] Similarly, the mevalonate pathway, regulated by enzymes like 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), controls the biosynthesis of cholesterol and isoprenoids, impacting low-density lipoprotein (LDL) cholesterol levels.^[13] Furthermore, the fatty acid desaturase 1 (FADS1) and FADS2 gene cluster are critical for the synthesis of polyunsaturated fatty acids, directly affecting the fatty acid composition in phospholipids, which exemplifies a genetically determined metabotype. ^[16] These pathways are subject to intricate metabolic regulation, including allosteric control and flux adjustments, ensuring that cellular demands for energy and building blocks are met.

Protein Glycation and Post-Translational Control

Glycylvaline’s significance is highlighted in the context of protein modification, particularly through non-enzymatic glycation. This process involves the slow attachment of glucose to amino groups, notably at N-terminal valine and internal lysine residues of proteins.^[17]A prominent example is the formation of glycated hemoglobin, where the concentration directly reflects the average blood glucose levels over an extended period (8–12 weeks), making it a vital clinical marker for glucose homeostasis.^[17] The enzymes hexokinase 1 (HK1) and glucokinase (GCK) are fundamental in glucose phosphorylation, regulating intracellular glucose concentrations and thereby indirectly influencing the extent of protein glycation.^[17]This post-translational modification is a key regulatory mechanism, linking glucose availability to long-term protein function and integrity.

Signaling and Network Integration

Cellular processes are not isolated but rather form an interconnected network of signaling pathways and molecular interactions. Intracellular signaling cascades, such as those involving mitogen-activated protein kinase (MAPK) pathways, are subject to regulation by proteins like tribbles, influencing diverse cellular responses. ^[18]These cascades often integrate signals from receptor activation, leading to the regulation of transcription factors that control gene expression, ultimately affecting metabolic and other cellular pathways. The interplay between different pathways, known as crosstalk, allows for a coordinated cellular response to environmental cues and internal states. For instance, genes involved in metabolic syndrome pathways, such as the leptin receptor (LEPR), hepatocyte nuclear factor 1-alpha (HNF1A), interleukin-6 receptor (IL6R), and glucokinase regulatory protein (GCKR), demonstrate how metabolic and inflammatory signaling pathways are interconnected, showcasing hierarchical regulation within complex biological networks. ^[14] Understanding this systems-level integration is crucial for comprehending emergent properties of the human metabolic network.

Genetic Influence on Metabolic Phenotypes and Disease

Genetic variation significantly impacts metabolic pathways, leading to distinct metabolic profiles or “metabotypes” that can predispose individuals to disease. Genome-wide association studies (GWAS) have identified numerous genetic polymorphisms that alter the homeostasis of key metabolites, providing functional insights into complex diseases.^[4] For example, variants in SLC2A9are strongly associated with serum uric acid levels, influencing the risk of gout.^[19] Similarly, polymorphisms in genes like HMGCRaffect cholesterol metabolism and LDL-cholesterol levels, impacting coronary artery disease risk.^[13]Dysregulation of these pathways due to genetic factors can lead to conditions such as type 2 diabetes, obesity, and lipid disorders. Identifying these genetically determined metabolic alterations not only enhances the understanding of disease mechanisms but also reveals potential therapeutic targets, offering avenues for individualized medication strategies.^[4]

Clinical Relevance

Diagnostic and Monitoring Utility

The glycylvaline moiety, particularly in the context of glycated hemoglobin (HbA1c), serves as a fundamental biomarker for evaluating long-term glycemic control. HbA1c is formed through the slow, non-enzymatic attachment of glucose to the N-terminal valine and internal lysine amino groups of hemoglobin, thereby reflecting the average blood glucose concentration over the preceding 8 to 12 weeks.^[20]This makes it a superior indicator of integrated mean glycemia compared to single, routine glucose measurements, providing a more stable and comprehensive picture of a patient’s glycemic status.^[21]

Clinically, HbA1c levels are indispensable for both the diagnosis of diabetes mellitus and the ongoing monitoring of treatment efficacy.^[22]A glycated hemoglobin concentration of 7.0% or higher has been established as a diagnostic threshold for drug-requiring diabetes, enabling the identification of individuals who require therapeutic intervention.^[23]The consistent use of HbA1c in monitoring allows healthcare providers to make informed adjustments to treatment regimens, assessing the impact of lifestyle modifications and pharmacological therapies on patient outcomes.

Prognostic Indicator for Metabolic and Cardiovascular Health

Beyond its role in diagnosis and monitoring, glycated hemoglobin carries significant prognostic implications, particularly concerning the development and progression of metabolic and cardiovascular diseases. Elevated HbA1c levels have been independently associated with an increased risk of adverse cardiovascular events, including stroke and coronary heart disease, even in older women without a prior diagnosis of diabetes and independently of fasting insulin and glucose levels.^[24]This highlights its utility as a powerful predictor of long-term cardiovascular morbidity and mortality.

Furthermore, in patients with established diabetes, intensive therapeutic strategies aimed at reducing glycated hemoglobin concentrations have been demonstrably effective in mitigating the development and progression of diabetes-related complications.^[25]Given that type 2 diabetes mellitus is a leading cause of morbidity and mortality, maintaining optimal glycated hemoglobin levels is crucial for improving patient prognosis and reducing the burden of disease.^[1]

Genetic Influences and Risk Stratification

The variability in glycated hemoglobin levels is partly attributable to genetic factors, offering avenues for risk stratification and the development of personalized medicine approaches. Genome-wide association studies have identified several genetic loci significantly associated with glycated hemoglobin concentrations, even within non-diabetic populations.^[1] For instance, common genetic variants within genes such as HK1, SLC30A8, and GCKhave shown consistent associations with glycated hemoglobin. Variants inGCKare known to influence fasting blood glucose, whileSLC30A8polymorphisms are linked to insulin secretion following glucose challenge, both of which are reflected in HbA1c levels.^[1]

These genetic insights can contribute to a more refined understanding of an individual’s predisposition to impaired glucose regulation and type 2 diabetes. While further research is essential, incorporating genetic information into clinical assessments could eventually facilitate the identification of high-risk individuals, allowing for earlier, more targeted prevention strategies and personalized treatment selection. Such approaches would complement existing clinical adjustments for covariates like age, menopause, and body mass index, moving towards a more individualized patient care model.^[1]

References

[1] Pare, G et al. “Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study.”PLoS Genetics, vol. 4, no. 12, 2008, p. e1000308.

[2] Yuan, X., et al. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” Am J Hum Genet, vol. 83, no. 4, 2008, pp. 520–528.

[3] Yang, Qiong, et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Medical Genetics, vol. 8, no. 1, 2007, p. S11.

[4] Gieger, C., et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, 2008.

[5] Sabatti, Chiara, et al. “Genome-Wide Association Analysis of Metabolic Traits in a Birth Cohort from a Founder Population.”Nature Genetics, vol. 40, no. 11, 2008, pp. 1321-26.

[6] Benyamin, Beben, et al. “Variants in TF and HFEexplain approximately 40% of genetic variation in serum-transferrin levels.”The American Journal of Human Genetics, vol. 84, no. 1, 2009, pp. 60-65.

[7] Kathiresan, S., et al. “Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.”Nat Genet, vol. 40, no. 2, 2008, pp. 189–197.

[8] Vasan, R. S., et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, vol. 8 Suppl 1, 2007, S2.

[9] Benjamin, Emelia J., et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Medical Genetics, vol. 8, no. 1, 2007, p. S10.

[10] Melzer, D., et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, vol. 4, no. 5, 2008, e1000072.

[11] Wallace, Chris, et al. “Genome-Wide Association Study Identifies Genes for Biomarkers of Cardiovascular Disease: Serum Urate and Dyslipidemia.”American Journal of Human Genetics, vol. 82, no. 1, 2008, pp. 139-49.

[12] McArdle, P. F., et al. “Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish.”Arthritis Rheum, 2007.

[13] Burkhardt, R., et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, 2008.

[14] Ridker, P. M., et al. “Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study.”Am J Hum Genet, vol. 82, no. 5, 2008, pp. 1185–1192.

[15] Doring, A., et al. “SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.”Nat Genet, 2008.

[16] Schaeffer, L., et al. “Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids.” Hum Mol Genet, vol. 15, no. 10, 2006, pp. 1745–1756.

[17] Pare, G., et al. “Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study.”PLoS Genet, vol. 5, no. 1, 2009, e1000312.

[18] Kiss-Toth, E., et al. “Human tribbles, a protein family controlling mitogen-activated protein kinase cascades.” J Biol Chem, vol. 279, no. 41, 2004, pp. 42703–42708.

[19] Vitart, V., et al. “SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.”Nat Genet, vol. 39, no. 9, 2007, pp. 1109–1117.

[20] Bunn, H. F. “Nonenzymatic glycosylation of protein: relevance to diabetes.” Am J Med, 1981.

[21] Nathan, D. M., et al. “Relationship between glycated haemoglobin levels and mean glucose levels over time.”Diabetologia, 2007.

[22] Singer, D. E., C. M. Coley, J. H. Samet, and D. M. Nathan. “Tests of glycemia in diabetes mellitus. Their use in establishing a diagnosis and in treatment.”Ann Intern Med, vol. 110, 1989, pp. 125–137.

[23] Peters, A. L., M. B. Davidson, D. L. Schriger, and V. Hasselblad. “A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels.”Jama, vol. 276, 1996, pp. 1246–1252.

[24] Lawlor, D. A., A. Fraser, S. Ebrahim, and G. D. Smith. “Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women.”PLoS Med, vol. 4, no. e263, 2007.

[25] The Diabetes Control and Complications Trial Research Group. “The effect of intensive treatment of diabetes on the development and progression of.” 1993.